# Primary Rituximab and Maintenance

> **NCT00140582** · PHASE3 · COMPLETED · sponsor: **Lymphoma Study Association** · enrollment: 1217 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00140582
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-05
- **Final completion:** 2016-12
- **Target enrollment:** 1217 (ACTUAL)
- **Last updated:** 2017-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140582, "Primary Rituximab and Maintenance". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT00140582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*